Lundbeck increases its share capital by 6,574 shares (0.0033 % of outstanding shares) as a result of exercise of employee warrants
November 20, 2018 05:51 ET
|
H. Lundbeck A/S
Valby, Nov. 20, 2018 (GLOBE NEWSWIRE) -- - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 32,870 as a consequence of the exercise of employee...
Lundbeck realized 12% growth in revenue (local currencies) and 56% growth in EPS in 9M 2018. Guidance for FY2018 raised
November 07, 2018 01:42 ET
|
H. Lundbeck A/S
Valby, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Financial report for the period 1 January to 30 September 2018 Lundbeck realized 12% growth in revenue (local currencies) and 56% growth in EPS in...
Lundbeck updates on clinical phase III study for Lu AF35700 in Treatment-Resistant Schizophrenia
October 25, 2018 10:34 ET
|
H. Lundbeck A/S
Valby, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Corporate Release Lundbeck updates on clinical phase III study for Lu AF35700 in Treatment-Resistant...
Lundbeck opdaterer om klinisk fase III studie af Lu AF35700 til behandlingsresistent skizofreni
October 25, 2018 10:34 ET
|
H. Lundbeck A/S
Valby, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Selskabsmeddelse Lundbeck opdaterer om klinisk fase III studie af Lu AF35700 til behandlings-resistent...
Takeda and Lundbeck submit New Drug Application (NDA) for vortioxetine in Japan for the treatment of Major Depressive Disorder (MDD)
September 28, 2018 03:30 ET
|
H. Lundbeck A/S
Copenhagen, Sept. 28, 2018 (GLOBE NEWSWIRE) -- NDA submission highlights four key studies involving approximately 1,400 patients, including the pivotal phase III study conducted in JapanPivotal...
Takeda og Lundbeck indsender registreringsansøgning (NDA) for vortioxetin i Japan til behandling af depression
September 28, 2018 03:30 ET
|
H. Lundbeck A/S
Copenhagen, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Registreringsansøgningen fremhæver fire nøglestudier, der omfatter cirka 1.400 patienter, herunder det pivotale fase III-studie udført i JapanDet...
Lundbeck realized 14% growth in revenue (local currencies) and 83% growth in EPS
August 08, 2018 01:09 ET
|
H. Lundbeck A/S
Valby, Aug. 08, 2018 (GLOBE NEWSWIRE) -- HIGHLIGHTS Revenue reached DKK 9,288 million in the first six months of 2018 representing an increase of 9% (14% in local currencies) compared...
Dr. Deborah Dunsire bliver ny administrerende direktør for Lundbeck
July 02, 2018 03:17 ET
|
H. Lundbeck A/S
Valby, Denmark, 2. juli 2018 - H. Lundbeck A/S (Lundbeck) har i dag offentliggjort, at bestyrelsen har udnævnt Dr. Deborah Dunsire som ny administrerende direktør for Lundbeck. Dr. Deborah Dunsire...
Dr. Deborah Dunsire named new President and CEO of Lundbeck
July 02, 2018 03:17 ET
|
H. Lundbeck A/S
Valby, Denmark, 2 July 2018 - H. Lundbeck A/S (Lundbeck) today announced that the Board of Directors of the company has appointed Dr. Deborah Dunsire as new president and CEO of Lundbeck. Dr. Dunsire...
Dr. Deborah Dunsire named new President and CEO of Lundbeck
July 02, 2018 02:41 ET
|
H. Lundbeck A/S
Valby, Denmark, 2 July 2018 - H. Lundbeck A/S (Lundbeck) today announced that the Board of Directors of the company has appointed Dr. Deborah Dunsire as new president and CEO of Lundbeck. Dr. Dunsire...